黑色素瘤治疗延误：潜在危机的风险因素分析。

Treatment Delay in Melanoma: A Risk Factor Analysis of an Impending Crisis.

机构信息

Drs. Elias, Schwartz, and Lambert are from the Division of Dermatology, Rutgers New Jersey Medical School, Newark. Dr. Lambert also is from the Department of Pathology, Immunology, and Laboratory Medicine. Dr. John is from the Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey.

出版信息

Cutis. 2021 Apr;107(4):E19-E26. doi: 10.12788/cutis.0235.

DOI:10.12788/cutis.0235

PMID:34096856

Abstract

Risk factors associated with melanoma treatment delay (MTD) have been inadequately studied. To elucidate MTD associations based on patient and tumor characteristics, a retrospective cohort study was performed for cutaneous melanoma cases reported to the National Cancer Database (NCDB) between 2004 and 2015. We evaluated the number of days from diagnosis to treatment initiation, analyzing postponements more than 45 days as moderate MTD (mMTD) and postponements more than 90 days as severe MTD (sMTD). Greater MTD rates were independently associated with patients who are older than 50 years, female, nonwhite, not privately insured, and treated at an academic facility and who have more advanced tumor stage and head/neck primaries.

摘要

与黑色素瘤治疗延迟（MTD）相关的风险因素尚未得到充分研究。为了根据患者和肿瘤特征阐明 MTD 相关性，对 2004 年至 2015 年间向国家癌症数据库（NCDB）报告的皮肤黑色素瘤病例进行了回顾性队列研究。我们评估了从诊断到治疗开始的天数，将超过 45 天的延迟分析为中度 MTD（mMTD），超过 90 天的延迟分析为严重 MTD（sMTD）。更高的 MTD 率与 50 岁以上、女性、非白人、没有私人保险、在学术机构接受治疗以及肿瘤分期更晚和头颈部原发性肿瘤的患者独立相关。